Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

In Vivo Epigenetic CRISPR Screen Identifies Asf1a as an Immunotherapeutic Target in Kras -Mutant Lung Adenocarcinoma

19 Nov 2019

Abstract excerpt

Abstract Despite substantial progress in lung cancer immunotherapy, the overall response rate in patients with KRAS-mutant lung adenocarcinoma (LUAD) remains low. Combining standard immunotherapy with adjuvant approaches that enhance adaptive immune responses—such as epigenetic modulation of antitumor immunity—is therefore an attractive strategy. To identify epigenetic regulators of tumor immunity, we constructed...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Extracellular vesicles in disease
Share to Immune cells in cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31744829
DOI: 10.1158/2159-8290.cd-19-0780

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

In Vivo Epigenetic CRISPR Screen Identifies Asf1a as an Immunotherapeutic Target in Kras -Mutant Lung AdenocarcinomaPMID 31744829Read ↗

KEAP1 mutation in lung adenocarcinoma promotes immune evasion and immunotherapy resistance.Semantic proximity Read ↗

Immunotherapy for Lung Malignancies: From Gene Sequencing to Novel Therapies.Semantic proximity Read ↗

KEAP1-Mutant Lung Cancers Weaken Anti-Tumor Immunity and Promote an M2-like Macrophage Phenotype.Semantic proximity Read ↗

Type I interferon signaling pathway enhances immune-checkpoint inhibition in KRAS mutant lung tumors.Semantic proximity Read ↗

Mutation of SMARCA4 Induces Cancer Cell-Intrinsic Defects in the Enhancer Landscape and Resistance to Immunotherapy.Semantic proximity Read ↗

Rasal1 impairment unleashes anticancer immunity - a focus on T cellsSemantic proximity Read ↗

Reprogramming the anti-tumor immune response via CRISPR genetic and epigenetic editingSemantic proximity Read ↗

<i>SMARCA4</i> mutation induces tumor cell-intrinsic defects in enhancer landscape and resistance to immunotherapySemantic proximity Read ↗

CRISPR/Cas9 edited tumor-associated immune cells in cancer immunotherapySemantic proximity Read ↗

SMARCA4 mutations in KRAS-mutant lung adenocarcinoma: a multi-cohort analysis.Semantic proximity Read ↗

Identification of VISTA regulators in macrophages mediating cancer cell survivalSemantic proximity Read ↗

<i>SMARCA4</i> Mutations in <i>KRAS</i>-mutant Lung Adenocarcinoma: A Multi-cohort AnalysisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.